Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Anlotinib as Consolidation Therapy in Limited-Stage SCLC
NCT07815223Phase 2Recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in small cell lung cancer (SCLC), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: Progression-Free Survival at 36 months and Overall Survival at 48 months. Started Nov 2025; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07815223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815223.